CO5580785A2 - Sal sodica cristalina del telmisartan y su uso como antagonista de angiotensina - Google Patents
Sal sodica cristalina del telmisartan y su uso como antagonista de angiotensinaInfo
- Publication number
- CO5580785A2 CO5580785A2 CO04042445A CO04042445A CO5580785A2 CO 5580785 A2 CO5580785 A2 CO 5580785A2 CO 04042445 A CO04042445 A CO 04042445A CO 04042445 A CO04042445 A CO 04042445A CO 5580785 A2 CO5580785 A2 CO 5580785A2
- Authority
- CO
- Colombia
- Prior art keywords
- telmisartan
- sodium salt
- crystalline sodium
- solution
- hydrates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1.- Sal sódica cristalina de Telmisartan de la fórmula 1 caracterizada por un punto de fusión de T=245±5°C.2.- Sal sódica cristalina de Telmisartan según la reivindicación 1, caracterizada porque en el diagrama de polvo radiológico tiene, entre otros, los valores característicos d = 20,95 Å, 17,72 Å, 13,97 Å y 13,63 Å.3.- Sal sódica cristalina de Telmisartan según una de las reivindicaciones 1 ó 2, caracterizada porque se presenta en forma de sus solvatos o hidratos, preferentemente en forma de sus hidratos.4.- Procedimiento para la preparación de la sal sódica cristalina de Telmisartan 1, caracterizado porque el ácido libre de Telmisartan se recoge en un disolvente adecuado, esta solución se mezcla a continuación con una sal sódica adecuada, en la que se añade por mol de Telmisartan al menos 1 mol de sal sódica, seguidamente la mezcla de reacción se calienta durante un espacio de tiempo de 15 minutos hasta 2 horas, a continuación la solución obtenida se filtra y el filtrado, obtenido de esta forma, se añade lentamente a un disolvente orgánico que se pueda calentar a una temperatura >40°C, partes del disolvente se separan por destilación eventualmente ya durante la adición del filtrado precedentemente mencionado, seguidamente la solución concentrada, así obtenida, se enfría y se aísla la sal sódica de Telmisartan que cristaliza en este caso y, eventualmente, tras el lavado con el disolvente orgánico mencionado inicialmente, se seca.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10153737A DE10153737A1 (de) | 2001-10-31 | 2001-10-31 | Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5580785A2 true CO5580785A2 (es) | 2005-11-30 |
Family
ID=7704331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04042445A CO5580785A2 (es) | 2001-10-31 | 2004-05-07 | Sal sodica cristalina del telmisartan y su uso como antagonista de angiotensina |
Country Status (35)
| Country | Link |
|---|---|
| EP (1) | EP1442023B1 (es) |
| JP (1) | JP5124076B2 (es) |
| KR (1) | KR100929502B1 (es) |
| CN (1) | CN100509789C (es) |
| AR (1) | AR037148A1 (es) |
| AT (1) | ATE370125T1 (es) |
| AU (1) | AU2002338886B2 (es) |
| BR (1) | BR0213568A (es) |
| CA (1) | CA2463146C (es) |
| CO (1) | CO5580785A2 (es) |
| CY (1) | CY1107504T1 (es) |
| DE (2) | DE10153737A1 (es) |
| DK (1) | DK1442023T3 (es) |
| EA (1) | EA007596B1 (es) |
| EC (1) | ECSP045089A (es) |
| ES (1) | ES2291505T3 (es) |
| HK (1) | HK1073841A1 (es) |
| HR (1) | HRPK20040372B3 (es) |
| HU (1) | HUP0402391A3 (es) |
| IL (2) | IL161165A0 (es) |
| ME (1) | MEP43608A (es) |
| MX (1) | MXPA04004013A (es) |
| MY (1) | MY129741A (es) |
| NO (1) | NO326465B1 (es) |
| NZ (1) | NZ532716A (es) |
| PE (1) | PE20030629A1 (es) |
| PL (1) | PL211462B1 (es) |
| PT (1) | PT1442023E (es) |
| RS (1) | RS50879B (es) |
| SA (1) | SA02230419B1 (es) |
| SI (1) | SI1442023T1 (es) |
| TW (2) | TWI333419B (es) |
| UA (1) | UA82833C2 (es) |
| UY (1) | UY27520A1 (es) |
| WO (1) | WO2003037876A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10319450A1 (de) * | 2003-04-30 | 2004-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Formulierung des Telmisartan Natriumsalzes |
| US9029363B2 (en) | 2003-04-30 | 2015-05-12 | Boehringer Ingelheim International Gmbh | Telmisartan sodium salt pharmaceutical formulation |
| US7692023B2 (en) | 2004-02-11 | 2010-04-06 | Teva Pharmaceutical Industries Ltd. | Candesartan cilexetil polymorphs |
| US20050250827A1 (en) * | 2004-05-05 | 2005-11-10 | Etinger Marina Y | Preparation of candesartan cilexetil in high purity |
| US7943781B2 (en) | 2004-10-18 | 2011-05-17 | Dr. Reddy's Laboratories Limited | Process for preparing telmisartan |
| US20060293377A1 (en) * | 2004-11-03 | 2006-12-28 | Shlomit Wizel | Amorphous and polymorphic forms of telmisartan sodium |
| EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
| EP2151450A1 (de) * | 2008-07-29 | 2010-02-10 | Sandoz AG | Verfahren zur Aufarbeitung von mikrobiologisch hergestellten zyklischen Oligopeptiden |
| WO2010133638A1 (de) | 2009-05-20 | 2010-11-25 | Boehringer Ingelheim Vetmedica Gmbh | Pharmazeutische telmisartan-trinklösung |
| EP2448575A2 (en) | 2009-07-02 | 2012-05-09 | Bilgic Mahmut | Pharmaceutical composition increasing solubility and stability |
| WO2011002423A2 (en) | 2009-07-02 | 2011-01-06 | Mahmut Bilgic | Solubility enhancing pharmaceutical composition |
| EP2632438A1 (en) | 2010-10-27 | 2013-09-04 | KRKA, tovarna zdravil, d.d., Novo mesto | Multilayer pharmaceutical composition comprising telmisartan and amlodipine |
| US9561610B2 (en) * | 2011-06-24 | 2017-02-07 | Honda Motor Co., Ltd. | Injection molding method and apparatus therefor |
| CR20190057A (es) | 2011-11-25 | 2019-04-23 | Adverio Pharma Gmbh | PROCEDIMIENTO DE PREPARACIÓN DE 5-FLUORO-1H-PIRAZOLOPIRIDINAS SUSTITUIDAS (Divisional 2014-0237) |
| US10385078B2 (en) | 2014-10-21 | 2019-08-20 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine |
| KR101872726B1 (ko) * | 2016-07-28 | 2018-06-29 | 주식회사 씨트리 | 텔미사르탄 메탄술폰산염 및 이를 포함하는 약제학적 조성물 |
| US10905676B2 (en) | 2017-07-07 | 2021-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats |
| JP2022517610A (ja) * | 2019-01-10 | 2022-03-09 | シーエスピーシー ゾンチー ファーマシューティカル テクノロジー（シージアチュアン）カンパニー，リミテッド | 複素環化合物塩およびその使用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5594003A (en) * | 1991-02-06 | 1997-01-14 | Dr. Karl Thomae Gmbh | Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists |
| SI9210098B (sl) * | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
| AU1791497A (en) * | 1996-02-29 | 1997-09-16 | Novartis Ag | At1 receptor antagonist for the stimulation of apoptosis |
| DE19901921C2 (de) * | 1999-01-19 | 2001-01-04 | Boehringer Ingelheim Pharma | Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels |
-
2001
- 2001-10-31 DE DE10153737A patent/DE10153737A1/de not_active Ceased
-
2002
- 2002-10-11 HU HU0402391A patent/HUP0402391A3/hu not_active Application Discontinuation
- 2002-10-11 PT PT02777305T patent/PT1442023E/pt unknown
- 2002-10-11 BR BR0213568-0A patent/BR0213568A/pt active Pending
- 2002-10-11 ME MEP-436/08A patent/MEP43608A/xx unknown
- 2002-10-11 EA EA200400479A patent/EA007596B1/ru not_active IP Right Cessation
- 2002-10-11 DK DK02777305T patent/DK1442023T3/da active
- 2002-10-11 WO PCT/EP2002/011394 patent/WO2003037876A1/de active IP Right Grant
- 2002-10-11 IL IL16116502A patent/IL161165A0/xx unknown
- 2002-10-11 RS YUP-363/04A patent/RS50879B/sr unknown
- 2002-10-11 AT AT02777305T patent/ATE370125T1/de active
- 2002-10-11 PL PL367477A patent/PL211462B1/pl unknown
- 2002-10-11 CA CA2463146A patent/CA2463146C/en not_active Expired - Fee Related
- 2002-10-11 SI SI200230594T patent/SI1442023T1/sl unknown
- 2002-10-11 KR KR1020047006317A patent/KR100929502B1/ko not_active IP Right Cessation
- 2002-10-11 MX MXPA04004013A patent/MXPA04004013A/es active IP Right Grant
- 2002-10-11 CN CNB028216202A patent/CN100509789C/zh not_active Expired - Fee Related
- 2002-10-11 NZ NZ532716A patent/NZ532716A/en not_active IP Right Cessation
- 2002-10-11 ES ES02777305T patent/ES2291505T3/es not_active Expired - Lifetime
- 2002-10-11 DE DE50210719T patent/DE50210719D1/de not_active Expired - Lifetime
- 2002-10-11 AU AU2002338886A patent/AU2002338886B2/en not_active Ceased
- 2002-10-11 EP EP02777305A patent/EP1442023B1/de not_active Expired - Lifetime
- 2002-10-11 JP JP2003540158A patent/JP5124076B2/ja not_active Expired - Lifetime
- 2002-10-28 UY UY27520A patent/UY27520A1/es not_active Application Discontinuation
- 2002-10-28 PE PE2002001061A patent/PE20030629A1/es not_active Application Discontinuation
- 2002-10-29 TW TW091132070A patent/TWI333419B/zh not_active IP Right Cessation
- 2002-10-29 MY MYPI20024051A patent/MY129741A/en unknown
- 2002-10-29 TW TW099114822A patent/TWI341200B/zh not_active IP Right Cessation
- 2002-10-30 AR ARP020104113A patent/AR037148A1/es active Pending
- 2002-11-05 SA SA02230419A patent/SA02230419B1/ar unknown
- 2002-11-10 UA UA20040503959A patent/UA82833C2/uk unknown
-
2004
- 2004-03-30 IL IL161165A patent/IL161165A/en not_active IP Right Cessation
- 2004-04-26 HR HR20040372A patent/HRPK20040372B3/xx not_active IP Right Cessation
- 2004-04-27 EC EC2004005089A patent/ECSP045089A/es unknown
- 2004-04-29 NO NO20041758A patent/NO326465B1/no not_active IP Right Cessation
- 2004-05-07 CO CO04042445A patent/CO5580785A2/es not_active Application Discontinuation
-
2005
- 2005-07-26 HK HK05106371.1A patent/HK1073841A1/xx not_active IP Right Cessation
-
2007
- 2007-10-15 CY CY20071101332T patent/CY1107504T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5580785A2 (es) | Sal sodica cristalina del telmisartan y su uso como antagonista de angiotensina | |
| ES2660146T3 (es) | Sales del inhibidor de cdk | |
| PE20020290A1 (es) | Polimorfos de analogos de epotilona de formula (i) | |
| PE20070318A1 (es) | Metodo para purificar tigeciclina | |
| PE20050948A1 (es) | Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
| PE20040844A1 (es) | Acidos fenilaceticos y derivados como inhibidores de la cox-2 | |
| PE20061490A1 (es) | Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1 | |
| PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
| AR010224A1 (es) | Metodo para preparar sales de litio | |
| AR070993A1 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-a]piridinas, composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1, tales como | |
| UY31014A1 (es) | Derivados de ftalazinona | |
| CU23873B1 (es) | Nuevo procedimiento para la preparación de un intermediario útil en la preparación de imidazotriazinonas sustituidas con sulfonamida | |
| AR048875A1 (es) | Un proceso para preparar montelukast y compuestos intermedios para el mismo | |
| AR004706A1 (es) | Un compuesto derivado de benzoxazina y pirido-oxazina utiles como antimicrobianos, composicion farmaceutica que lo contienen, un metodo para preparar dichos compuestos e intermediarios utiles para dicho metodo. | |
| AR009379A1 (es) | Derivados de acido piperidin-cetocarboxilico, su uso y composiciones farmaceuticas que los contienen | |
| UY26454A1 (es) | Cristal de 4-carboxamino-1,2,3,4-tetrahidroquinolina 2-sustituida | |
| PE20061014A1 (es) | Clorhidrato de lercanidipina amorfo | |
| ES2278552T1 (es) | Preparacion de intermediarios de tadalafil. | |
| ES2818736T3 (es) | Método de fluoración aromática | |
| AR066603A1 (es) | Derivados de arilamida pirimidona | |
| AR060064A1 (es) | Compuestos sustituidos de tetrahidroisoquinolina, su preparacion y su uso en medicamentos para el tratamiento de enfermedades mediadas por los receptores 5-ht6 | |
| AR052949A1 (es) | Metabolitos derivados de piridina como antagonistas nk-1 para emesis | |
| AR079294A1 (es) | Acidos homoglutamico y acidos glutamico marcados con yodo y metodo de preparacion de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |